BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services Contract Manufacturing

Samsung Biologics Reports Second Quarter 2022 Financial Results

Released consolidated financial position of the company based on its full acquisition of Samsung Bioepis completed on April 20, 2022 Achieved recor...

July 28, 2022 | News

WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore

This investment will establish a cutting-edge, fully integrated CRDMO center in Singapore, including a research and development service center and large-...

July 20, 2022 | News

Samsung Biologics to purchase land for its second Bio Campus

Acquires additional land, sized 357,366㎡ valued at KRW 426 billion, for Bio Campus 2 Plans to build Multi-Modal Plant, Open Innovation,...

July 19, 2022 | News

GenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs

Through this agreement, both companies will strategically cooperate in the overall development process, such as discovery, manufacturing, and clinical tria...

July 15, 2022 | News

GenScript ProBio Signs MOU to Form Strategic Partnership with ACT Therapeutics to Development of New CAR-T Cell Therapies

GenScript ProBio and ACT Therapeutics are in the process of signing a contract for plasmid and virus vector development and production for the first pipe...

July 13, 2022 | News

'Sustainable CDMO' Samsung Biologics releases 2022 ESG Report

Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its operations, moving towards 100% renewable energy. Details n...

July 12, 2022 | News

WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates

Under the partnership, AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing, ADC conjugation process developm...

July 08, 2022 | News

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Chan...

July 07, 2022 | News

WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products

WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG14 fac...

July 05, 2022 | News

Catalent Expands Primary Packaging Capabilities at its Clinical Supply Facility in Shiga, Japan

The new blister packaging equipment is identical to that available across Catalent's clinical supply services network, offering maximum access and flexibil...

June 30, 2022 | News

WuXi STA Opens A High-Potency API Plant

The new plant adopts advanced isolation technologies with the capability to handle potent compounds with Occupational Exposure Limit (OEL) as low as 10 ng/...

June 29, 2022 | News

Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies

Expansion doubles production of the most highly potent active pharmaceutical ingredients (HPAPIs) Merck now one of industry’s largest manufacturer...

June 24, 2022 | News

ProteoNic Announces Licensing of its 2G UNic™ Technology Platform for Production of Biologics to GenScript ProBio

Under the agreement, GenScript ProBio gains access to ProteoNic technology for the development of high-yielding cell lines for its clients. As a result, Ge...

June 15, 2022 | News

WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes

WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-...

June 06, 2022 | News

Stay Connected